Navigation Links
Whistleblowers' Complaints Lead Eli Lilly to Pay $800 Million to Settle Civil Medicaid Fraud Charges, According to Berg & Androphy
Date:1/15/2009

HOUSTON, Jan. 15 /PRNewswire/ -- The $800 million settlement that Eli Lilly and Company (NYSE: LLY) has agreed to pay to settle civil False Claims Act charges related to allegedly false or fraudulent marketing, promotion and sale of its drug Zyprexa can be traced to the courageous stands taken by employee whistleblowers, according to the Berg & Androphy law firm.

The company's settlement with the federal government, which also includes a guilty plea in a separate criminal action, covers allegations that occurred between September 1999 and December 2005 related to practices prohibited by the federal Food and Drug Administration (FDA) such as the distribution of "misbranded" drugs.

In March, 2005, a whistleblower represented by Joel M. Androphy and Sarah Frazier, of Berg & Androphy in Houston, filed a qui tam action in the U.S. District Court for the Eastern District of N.Y. ("United States v. Eli Lilly," Case No. CV051471) that was transferred to the Eastern District of Pennsylvania (Case No. CV-06-2909).

The whistleblower represented by Berg & Androphy complained of Lilly's illegal marketing, promotion and sale of Zyprexa to children and in higher- than-recommended dosages to adults. The whistleblower also alleged that as part of the marketing and promotional schemes, Lilly encouraged physicians by means of monetary payments.

Mr. Androphy, who authored the book "Federal False Claims Act and Qui Tam Litigation" (Law Journal Press), said, "Our whistleblower client, who resides in New Jersey, is no longer in the pharmaceutical business, but he is proud of the stand he took in this case. He and the eight other whistleblowers who filed lawsuits deserve credit for exposing the conduct alleged in the settlement agreement."

Of the total settlement, $438 million will go to the federal government, and up to $362 million will go to states except those that are pursuing separate litigation. The states have not yet concluded negotiations, but it is believed that most states will accept a share of the settlement. Multiple relators will receive 18 percent of the settlement amounts. The relators' share of the federal settlement is more than $78 million, and could increase to more than $100 million after the resolution of state claims. Lilly also will be obligated to pay legal fees to the relators' attorneys.

The False Claims Act is a Lincoln-era law that allows private citizens with knowledge of fraud on the government to sue and share in the proceeds of any recovery. The law was enacted to combat widespread procurement fraud in the Civil War, but it fell into disuse in the 1940s. Amendments passed in 1986 made the False Claims Act the government's chief weapon in its war on fraud, and the Justice Department used it in its investigations of clinical laboratories and defense contractors in the mid-1990s. In pharmaceutical cases alone, more than $1 billion has been returned to the federal treasury through False Claims Act lawsuits.

     Attorney Contacts: Joel Androphy and Sarah Frazier, Berg & Androphy,
     Houston, 713.529.5622,http://www.bafirm.com.

     Media Contact: Erin Powers, Powers MediaWorks LLC, for Berg & Androphy,
     281.703.6000.

'/>"/>
SOURCE Berg & Androphy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo
2. More marital happiness = less sleep complaints
3. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
4. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
5. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
6. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
7. Lillys CEO Calls for Reform of Nations Drug Safety System
8. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
9. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
10. Lilly Delivers Strong Third-Quarter Results
11. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning ... will begin serving as new board chair for Orange County health care system ... the remainder of soon-to-be former chair Mark Refowitz’s term, which runs through June ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ... Success website has recently developed and published an informational resource that addresses frequently ... based on common inquiries the site’s team of third party administrator (TPA) contributors ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... skin is a common and unwelcomed occurrence in people of all ages, genders and ethnicities. ... the discussion of dealing with excess skin oil. “Oily skin is a challenge to many ... help remove the oily shine while keeping the skin fresh and clean,” says Dr. Au. ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep ... apnea treatment, with or without a referral. Sleep apnea is often left untreated because ... sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/27/2017)... March 27, 2017 The National University ... and data analytics company, signed a Memorandum of ... healthcare delivery in the region. ... Health Research and Technology (BIGHEART) at NUS and ... topics related to healthcare IT and medical device ...
(Date:3/27/2017)... , March 27, 2017 ... better understand Eli Lilly and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
Breaking Medicine Technology: